Deborah Dunsire aims for 10 European Vyepti launches this year

A series of Vyepti launches is slated to begin within the next half year, with Lundbeck preparing the migraine drug for as many as 10 European countries this year, according to CEO Deborah Dunsire.

Deborah Dunsire, CEO of Lundbeck | Photo: Gregers Tycho/ERH

In January, Lundbeck received the much anticipated European approval of migraine drug Vyepti, and the pharmaceutical company has great expectations for the treatment.

”We will now begin rolling it out in different countries. This will take a little time. We have an external supplier with which we will plan the production of the specific packages for the different countries. So, it won’t necessarily be available from one day to the other,” says CEO at Lundbeck Deborah Dunsire to MedWatch.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs